NFKB1 and diabetes mellitus: Dihydromyricetin has been shown to ameliorate reductions in diastolic and systolic function and conduction abnormalities induced by diabetes by downregulating HMGB1 and inhibiting the phosphorylation of NF-κB p65 (50).